• Xilio posted a Q2 net loss of USD 6.4 million, narrowing from a USD 15.8 million loss a year earlier.
• Revenue more than doubled to USD 18.7 million, driven by higher recognition under AbbVie and Gilead agreements.
• R&D expenses dipped to USD 14.6 million; G&A costs climbed to USD 7.6 million on higher personnel-related costs.
• Cash and cash equivalents totaled USD 136 million as of June 30, 2026; runway projected into Q1 2028.
• FDA cleared the IND for XTX501; Phase 1 dosing expected in H2 2026, with initial NSCLC data slated for H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120730PRIMZONEFULLFEED9808355) on August 12, 2026, and is solely responsible for the information contained therein.